Last updated: 2026-09-09 04:53:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
LB Pharmaceuticals Inc. (LBRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $49.35, with a market capitalization of $1.59B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.36 to $50.18. This page covers its latest market performance, valuation, price trends and company information.
$1.59B | |
$48.53 | |
$50.18 | |
$13.36 | |
$49.34 | |
274.12K | |
338.46K | |
-- | |
$50.18 | |
$13.36 | |
-- | |
-- |
LB Pharmaceuticals Inc. (LBRX) last closed at $49.34 as of 2026-09-08 23:55:00, unchanged from the previous close of $49.34.
During the latest regular trading session, LBRX traded between $13.36 and $50.18, with a volume of 274.12K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, LB Pharmaceuticals Inc. (LBRX) moved from $47.89 to $49.35, representing a gain of 3.06% ($1.46).
The stock traded between $46.37 and $50.18 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 297.49 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 97.8%
LBRX is currently trading at $49.35, placing it 97.8% of the way from its 52-week low of $13.36 to its 52-week high of $50.18. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 27 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of LB Pharmaceuticals Inc. (LBRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.